Study of HuL001 for multiple myeloma that has come back or not responded
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called HuL001 combined with lenalidomide and dexamethasone for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. It aims to see if this combination can help when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have multiple myeloma that has come back or not responded after at least three prior treatments, or after two treatments that included three different drug types (like an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory drug).
- You must have measurable signs of the disease, such as a certain level of M-protein in your blood or urine.
- You must be in fairly good health (able to do daily activities) and have adequate organ function (like blood counts and kidney function).
- You must agree to use effective contraception if you are able to have children.
- You cannot have certain medical conditions like active infections, recent major surgery, or other cancers that haven't been treated and cleared.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SENL103 for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. It's a single-arm study, meaning everyone gets the investigational drug.
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This trial tests a combination of three drugs (mezigdomide, carfilzomib, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this new drug mix can help control the cancer again.
This trial tests a new treatment called OL-101 for people whose multiple myeloma has come back or stopped responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. It aims to see if OL-101 can help control the disease.
Hear when a new Multiple Myeloma Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.